Overview

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Status:
Active, not recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Theravance Biopharma